Review paper<br>Efficacy and safety of TNF inhibitors – results of randomized controlled clinical trials

Anna Filipowicz-Sosnowska

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2006
vol. 44

Send email

Copy url:

abstract:

Review paper
Efficacy and safety of TNF inhibitors – results of randomized controlled clinical trials

Anna Filipowicz-Sosnowska

Reumatologia 2006; 44, 6: 309–314

Online publish date: 2006/12/15

View full text Get citation

TNF inhibitors were first approved for treatment of active rheumatoid arthritis (RA) in 1998. Since that time, a series of multicentre, randomized controlled trials have been evaluated in early and established RA, in patients who had not been treated with methotrexate (Mtx) as well as in those who had an inadequate response to traditional disease modifying antirheumatic drugs (DMARD), including Mtx. In these trials approximately 6000 RA patients have participated. Clinical response to treatment and adverse effects of anti-TNF agents are discussed. The relative expense of TNF inhibitors makes their universal use impractical. The use of TNF inhibitors in the treatment of active RA should be considered when traditional DMARD, including combination therapy of DMARD, are not effective.

keywords:

rheumatoid arthritis, TNF-inhibitors, randomization, controlled clinical trials

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Review paperEfficacy and safety of TNF inhibitors – results of randomized controlled clinical trials

Anna Filipowicz-Sosnowska

rheumatoid arthritis, TNF-inhibitors, randomization, controlled clinical trials

Review paper
Efficacy and safety of TNF inhibitors – results of randomized controlled clinical trials